🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "major milestone" in the effort against drug-resistant strains of the infection, according to scientists.

A Global Health Concern

The sexually transmitted infection are increasing around the world, with data suggesting over 82 million infections per year. Particularly high rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, also known as a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone marks a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

According to results detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which uses two antibiotics. The trial included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Clinicians on the front lines have expressed hope. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as essential to reduce the burden of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.